Clinical trials: Recurrent NSCLC
Carcinoma, Non-small-cell Lung
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
This is a Phase I/IIa study to evaluate safety and efficacy of dalotuzumab (MK-0646) in combination with erlotinib in participants with recurrent Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00654420
- Testing
- Dalotuzumab, Erlotinib
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC